Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells $1,003,500.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of Liquidia stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,466,934 shares of the company’s stock, valued at approximately $58,882,730.76. This represents a 1.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The stock was sold at an average price of $40.00, for a total value of $132,000.00.
• On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total value of $1,256,387.28.
• On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total value of $859,891.96.
• On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total value of $1,003,000.00.

Liquidia Price Performance

NASDAQ LQDA opened at $39.47 on Friday. Liquidia Corporation has a one year low of $11.85 and a one year high of $46.67. The stock has a 50-day moving average of $36.55 and a 200 day moving average of $33.33. The company has a market capitalization of $3.48 billion, a price-to-earnings ratio of -47.55 and a beta of 0.45. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The company had revenue of $92.02 million during the quarter, compared to the consensus estimate of $87.49 million. The firm’s revenue was up 3072.4% compared to the same quarter last year. On average, sell-side analysts forecast that Liquidia Corporation will post -1.51 EPS for the current year.

Wall Street Analyst Weigh In

LQDA has been the subject of several research analyst reports. BTIG Research lifted their price objective on Liquidia from $49.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Needham & Company LLC lifted their price objective on Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Lifesci Capital upgraded Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Wells Fargo & Company lifted their price objective on Liquidia from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Monday, March 23rd. Finally, Jefferies Financial Group lifted their price objective on Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, January 13th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $43.44.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Earnings beat and improving near‑term fundamentals — Liquidia reported quarterly revenue and EPS above consensus, which supports the company’s growth thesis and likely attracted buyer interest ahead of the pullback. MarketBeat: Liquidia Stock
• Positive Sentiment: Analyst support remains constructive — several firms have raised price targets or reiterated buy/overweight opinions recently, providing research‑driven demand that can limit downside. MarketBeat: Analyst Coverage
• Neutral Sentiment: High institutional ownership (~64.5%) — large holders can stabilize the share price; insider sales don’t automatically become sustained selling if institutions remain supportive. MarketBeat: Institutional Holdings
• Negative Sentiment: Concentrated insider selling by C‑suite — multiple sizable sales from CFO Michael Kaseta (including multi‑hundred‑thousand and multi‑million dollar blocks) have been disclosed and are likely the main reason shares pulled back today; the volume and visibility of these sales can damage sentiment. InsiderTrades: Kaseta Sale
• Negative Sentiment: CEO and other officers also sold under 10b5‑1 plans — Roger Jeffs disclosed multi‑date sales (including a 25,000‑share block), reinforcing the perception of distributed insider exits that can cap near‑term upside even if planned. SEC Filing: Jeffs Sale

Institutional Investors Weigh In On Liquidia

Large investors have recently made changes to their positions in the company. Farallon Capital Management LLC grew its stake in shares of Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after acquiring an additional 4,326,876 shares during the period. TCG Crossover Management LLC bought a new position in shares of Liquidia during the 3rd quarter valued at approximately $38,887,000. Caprock Group LLC bought a new position in shares of Liquidia during the 3rd quarter valued at approximately $37,114,000. MPM Bioimpact LLC grew its stake in shares of Liquidia by 600.4% during the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after acquiring an additional 1,200,869 shares during the period. Finally, Voloridge Investment Management LLC bought a new position in shares of Liquidia during the 3rd quarter valued at approximately $12,571,000. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).